High-throughput methods for measuring autoantibodies in systemic lupus erythematosus and other autoimmune diseases.
Numerous groups have now validated high-throughput approaches to autoantibody profiling in a variety of systems. Recently, we have used autoantigen microarray technology to identify distinct autoantibody profiles in H-2 congenic MRL/lpr mice (Sekine et al., manuscript in preparation), and we are expanding this platform to study human and mouse models of IDDM and RA. We are also developing protein arrays for multiplex analysis of serum antibody isotypes. Multiplexed methods for autoantibody profiling will undoubtedly continue to uncover novel aspects of autoimmunity and B cell biology. It is now time to move these technologies beyond the proof-of-concept phase, and start addressing the next series of important questions. These include, but certainly are not limited to: identifying "autoantibody signatures" associated with disease state or outcome; profiling autoantibodies during the natural course of murine and human disease; and monitoring changes in autoantibody profiles of patients in response to therapeutic intervention. However, the next set of challenges is just right around the corner. As data and statistical analysis tools become more robust, it will be possible to generate and approach new hypotheses at an unprecedented pace.
Graham
Kareem L
KL
Division of Immunology and Rheumatology, Department of Medicine, VA Palo Alto Health Care System, Palo Alto, CA 94304, USA. kareem.graham@stanford.edu
Robinson
William H
WH
Steinman
Lawrence
L
Utz
Paul J
PJ
D001323:Autoantibodies / Q000032:analysis* / Q000276:immunology; D015415:Biomarkers; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis* / Q000276:immunology
D001323:Autoantibodies; D015415:Biomarkers